Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 3/20 | 0.31 |
| ▸ | NOS1 | P29475 | 3/20 | 0.31 |
| ▸ | NOS2 | P35228 | 3/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | GUSB | P08236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20816015 | 0.98 | ALOX5 (0.42) | ALOX5SPHK1ALDH1A1SPHK2EPHX1 | |
| SCHEMBL20816024 | 0.94 | CYP1A2 (0.37) | ALOX5SPHK1CYP1A2NOS1NOS2 | |
| SCHEMBL30358422 | 0.85 | NOS1 (0.32) | NOS1NOS2 | |
| SCHEMBL20816002 | 0.82 | CYP1A2 (0.32) | CYP1A2NOS1NOS2NOS3DPP4 | |
| SCHEMBL30358428 | 0.79 | DPP4 (0.37) | ALOX5SPHK1ALDH1A1SPHK2EPHX1 | |
| SCHEMBL38660958 | 0.77 | ALOX5 (0.39) | ALOX5SPHK1ALDH1A1SPHK2EPHX1 | |
| SCHEMBL20844321 | 0.77 | ALOX5 (0.40) | ALOX5SPHK1ALDH1A1SPHK2EPHX1 | |
| SCHEMBL30358419 | 0.76 | — | — | |
| SCHEMBL462039 | 0.75 | — | — | |
| SCHEMBL2877408 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630661-B2 | Additives useful in 3D printing technologies | Evonik Operations GmbII (DE) | 2026-05-19 | — | — | US | claimed |
| CN-115960328-A | Additives for 3D printing techniques | 赢创运营有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-115960328-A | Additives for 3D printing techniques | 赢创运营有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-10246588-B1 | Solvent-free resin composition and uses of the same | TAIWAN UNION TECHNOLOGY CORPORATION (TW) | 2019-04-02 | — | — | US | disclosed |
| US-20190085166-A1 | SOLVENT-FREE RESIN COMPOSITION AND USES OF THE SAME | TAIWAN UNION TECHNOLOGY CORPORATION (TW) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630661-B2 | Additives useful in 3D printing technologies | HTR3D, HTR3B, HTR3C | ALOX5 2166/4885SPHK1 3521/4885ALDH1A1 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.